Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Respilac is a preservative-free ophthalmic solution developed by Sooft Italia Spa for the treatment of moderate dry eye disease (DED), particularly in contact lens wearers. The formulation contains 2.0% lipidure (2-methacryloyloxyethyl phosphorylcholine, or MPC) and 0.1% hypromellose (HPMC). Lipidure is a biomimetic polymer characterized by high biological compatibility and moisture retention, which protects corneal epithelial cells and contact lenses from desiccation damage. Hypromellose serves as a lubricant and viscosity-increasing agent to stabilize the tear film and reduce ocular surface stress. Clinical studies have demonstrated that Respilac is non-inferior to standard HPMC-based artificial tears in improving ocular tolerability and reducing symptoms such as burning, itching, and foreign body sensation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Respilac.